Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Biochemical Test Facilitates Diagnosis of Alzheimer's Disease

By LabMedica International staff writers
Posted on 24 May 2011
An innovative biochemical test has been designed that can identify a brain hormone in the blood of patients with Alzheimer's disease (AD). More...


A clinical study has shown that a noninvasive blood test, based on a biochemical process, may be successfully used to diagnose Alzheimer's at an early stage and differentiate it from other types of dementia.

Scientists at McGill University Health Center (MUHC; Montreal, QC, Canada) based the Alzheimer's blood test on the production of a brain hormone called dehydroepiandrosterone (DHEA). This hormone is present at high levels in the brain where it has a wide range of biological effects. A total of 86 subjects were included in this study: 19 male and 20 female AD patients; 18 male and 22 female age-matched controls; and 4 men and 3 women with mild cognitive impairment. The scientists were able to promote the production of DHEA, using a chemical process called oxidation, in blood taken from non-Alzheimer's patients. However, serum oxidation, by way of ferrous iron (Fe2+), on the blood from Alzheimer's patients did not result in an increase of DHEA.

Currently the diagnosis of Alzheimer's follows the sequence of family history, information, mental assessment and the physical exam, focusing on neurological signs. Vassilios Papadopoulos, D.Pharm., PhD, a lead author of the study, said, "There is a clear correlation between the lack of ability to produce DHEA through oxidation in the blood and the degree of cognitive impairment found in Alzheimer's disease. We demonstrated we could accurately and repetitively detect Alzheimer's disease, with small samples of blood. This test also allowed for differential diagnosis of early stages of Alzheimer's disease, suggesting this can be used as a test to diagnose the disease in its infancy."

Professor Papadopoulos believes that an accurate, easy, and specific noninvasive biochemical test that correlates with clinical findings is vital. The results of the study demonstrate that the DHEA-oxidation blood test can be used to diagnose AD at a very early stage and monitor the effect of therapies and the evolution of the disease. The study was published in April 2011, in the Journal of Alzheimer's Disease.

Related Links:

McGill University Health Center



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Collection and Transport System
PurSafe Plus®
Blood Glucose Test Strip
AutoSense Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The VITROS hs Troponin I Assay is designed for use on VITROS Systems (Photo courtesy of QuidelOrtho)

High-Sensitivity Troponin I Assay Aids in Diagnosis of Myocardial Infarction

Heart disease remains the leading cause of death for adults over 45 in the United States, accounting for nearly one in three deaths. In 2023 alone, 919,032 Americans died from cardiovascular disease —... Read more

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.